Selective Androgen Receptor Modulators (SARMs) in the World of Sports

Background: The study aims to investigate the effects of selective androgen receptor modulators (SARMs) among athletes and examine the possible beneficial results and risks of these substances for the athletes' health and performance and human health in general. Nowadays, SARMs have become a focus of interest in the world of sports and medicine. Because of their anabolic action, SARMs are considered quite promising for treating several disorders including breast cancer, osteoporosis, DMD (Duchenne Muscular Dystrophy), some type of tumors, etc. As for the athletic community, SARMs are used as doping for muscle mass increasing and strengthening and pose as an alternative to other steroid-based doping with their minimum side effects. SARMs are innovative substances for athletic performance and human health. Further study on SARMs is required in order to understand the long-term effects on human health and athletic performance.

[1]  L. Lipshultz,et al.  Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. , 2019, Sexual medicine reviews.

[2]  A. Miklos.  SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMs) IN THE CONTEXT OF DOPING , 2018, FARMACIA.

[3]  I. Goldstein,et al.  The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review , 2018, Menopause.

[4]  J. Henck,et al.  Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients , 2018, Andrology.

[5]  U. Habel,et al.  Exogenous Testosterone Enhances the Reactivity to Social Provocation in Males , 2018, Front. Behav. Neurosci..

[6]  S. Anker,et al.  Therapeutic considerations of sarcopenia in heart failure patients , 2018, Expert review of cardiovascular therapy.

[7]  J. Dalton,et al.  Development of selective androgen receptor modulators (SARMs) , 2017, Molecular and Cellular Endocrinology.

[8]  S. Basaria,et al.  Adverse health effects of androgen use , 2017, Molecular and Cellular Endocrinology.

[9]  C. Serafinceanu,et al.  TESTOSTERONE THERAPY, NEW OPPORTUNITIES IN DIABETES MELLITUS , 2018 .

[10]  Katsuji Aikawa,et al.  Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models. , 2017, Oncology letters.

[11]  R. V. Clark,et al.  Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women , 2017, British journal of clinical pharmacology.

[12]  J. Dalton,et al.  Androgen Receptor: A Complex Therapeutic Target for Breast Cancer , 2016, Cancers.

[13]  Duane D. Miller,et al.  Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling , 2014, PloS one.

[14]  Edward D. Kim,et al.  Anabolic steroid-induced hypogonadism: diagnosis and treatment. , 2014, Fertility and sterility.

[15]  A. Dobs,et al.  Enobosarm (GTx-024, S-22): a potential treatment for cachexia. , 2014, Future oncology.

[16]  J. Dalton,et al.  Selective androgen receptor modulators for the treatment of late onset male hypogonadism , 2014, Asian journal of andrology.

[17]  Chris P. Miller,et al.  Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. , 2014, Endocrinology.

[18]  Yasuhiko Takahashi,et al.  A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate. , 2013, European journal of pharmacology.

[19]  A. De Luca,et al.  GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. , 2013, Pharmacological research.

[20]  L. Kunkel,et al.  The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. , 2013, The Journal of cell biology.

[21]  D. Papanicolaou,et al.  A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia , 2013, The journal of nutrition, health & aging.

[22]  A. Dobs,et al.  Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. , 2013, The Lancet. Oncology.

[23]  Shalender Bhasin,et al.  The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[24]  S. Yamada,et al.  Anti‐androgenic effects of S‐40542, a novel non‐steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia , 2012, The Prostate.

[25]  J. Dalton,et al.  The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial , 2011, Journal of cachexia, sarcopenia and muscle.

[26]  Duane D. Miller,et al.  Nonsteroidal Selective Androgen Receptor Modulators Enhance Female Sexual Motivation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[27]  Wilhelm Schänzer,et al.  Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. , 2009, Drug testing and analysis.

[28]  Duane D. Miller,et al.  Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats , 2007, Pharmaceutical Research.

[29]  Duane D. Miller,et al.  Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. , 2005, Endocrinology.

[30]  Duane D. Miller,et al.  Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates , 2005 .

[31]  J. Dalton,et al.  Discovery and therapeutic promise of selective androgen receptor modulators. , 2005, Molecular interventions.

[32]  G. Forti,et al.  Testosterone and sexual activity. , 2005, Journal of endocrinological investigation.

[33]  Seiji Amano,et al.  Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. , 2003, Biological & pharmaceutical bulletin.

[34]  A. Bosy-Westphal,et al.  The age-related decline in resting energy expenditure in humans is due to the loss of fat-free mass and to alterations in its metabolically active components. , 2003, The Journal of nutrition.

[35]  Eli Carmeli,et al.  The biochemistry of aging muscle , 2002, Experimental Gerontology.

[36]  H. Morris,et al.  Effects of Dihydrotestosterone on Bone Biochemical Markers in Sham and Oophorectomized Rats , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  S. di Somma,et al.  Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. , 1996, JAMA.

[38]  K. Frankel,et al.  The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. , 1976, Human pathology.